Trial Profile
Phase 2 Clinical Trial to Evaluate Efficacy and Safety of SM-88 Used With Methoxsalen, Phenytoin, and Sirolimus (MPS) as Maintenance Therapy Following Standard Treatments for Ewing's Sarcoma or as Salvage Therapy for Advanced Sarcomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs Racemetyrosine (Primary) ; Methoxsalen; Phenytoin; Sirolimus
- Indications Ewing's sarcoma; Haemangiosarcoma; Leiomyosarcoma; Sarcoma
- Focus Therapeutic Use
- Acronyms HopES
- 16 Apr 2024 Planned End Date changed from 31 Oct 2023 to 31 Mar 2025.
- 16 Apr 2024 Planned primary completion date changed from 31 Oct 2022 to 19 Dec 2024.
- 19 Jan 2023 Status changed from recruiting to active, no longer recruiting.